Wyeth gets Pristiq approved (a derivative of Effexor) for Major Depressive Disorder.
Speaking of anti-depressants, lots of noise being made – and arguments back and forth – about whether they are effective at all.
Very encouraging results for Novartis‘ new kidney cancer drug Everolimus – late-stage testing was stopped early because of significant survival benefits in patients.
Centocor launches a blog (more pharmas should). Here’s the what and why.
Biogen‘s Tysabri linked to liver damage.
More bad news for EPOs. Links to blood clots and death.
The Schering/Organon merger produces the expected job cuts.
Why did drug costs slow down in 2007? A bumper crop of generics.
Pharma still taking baby steps on the web, according to article on Pharma Exec website.